- cafead   Oct 31, 2023 at 10:23: AM
via Eli Lilly has agreed to buy a gene-editing program for cardiovascular diseases from Beam Therapeutics in a deal, valued at up to $600 million, that ties in with the biotech’s recent restructuring drive.
article source
article source